Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 8/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84462 | 0.81 | TRPA1 (0.54) | METAP2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL14349688 | 0.78 | IDO1 (0.42) | METAP2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL84390 | 0.78 | MAPT (0.60) | METAP2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3912740 | 0.76 | UGT2B7 (0.45) | MEN1KMT2AALDH1A1KIF11TRPA1 | |
| SCHEMBL12125845 | 0.74 | HCAR2 (0.47) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL12123553 | 0.74 | DHPS (0.43) | METAP2HCAR2KIF11TRPA1CDK2 | |
| SCHEMBL12808612 | 0.73 | EIF4A3 (0.40) | METAP2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL20350398 | 0.73 | EIF4A3 (0.46) | METAP2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL8434760 | 0.72 | ALDH1A1 (0.51) | METAP2KDM4EMEN1MAPTKMT2A | |
| SCHEMBL13561663 | 0.72 | KIF11 (0.47) | KDM4EMEN1MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865381-A1 | ITK inhibitors for treating blood cell malignancies | Pharmacyclics, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20090170891-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-07-02 | — | — | US | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | METAP2 3506/4885KDM4E 4824/4885MEN1 2028/4885 |
| US-20090170891-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | METAP2 3506/4885KDM4E 4824/4885MEN1 2028/4885 |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | METAP2 3555/4885KDM4E 4813/4885MEN1 1955/4885 |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | METAP2 3574/4885KDM4E 4832/4885MEN1 2100/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | METAP2 3202/4885KDM4E 4792/4885MEN1 3094/4885 |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | METAP2 3555/4885KDM4E 4813/4885MEN1 1955/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | METAP2 3506/4885KDM4E 4824/4885MEN1 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.